GlaxoSmithKline Pharmaceuticals has announced its audited financial results for the year ended March 31, 2026. The company reported a consolidated profit of Rs. 103,598 lakhs for the fiscal year. The Board of Directors has recommended a final dividend of Rs. 57 per equity share, subject to shareholder approval at the upcoming 101st Annual General Meeting scheduled for June 30, 2026. The record date for the dividend entitlement is set for May 29, 2026.
Financial Performance Overview
For the financial year ended March 31, 2026, GlaxoSmithKline Pharmaceuticals achieved consolidated revenue from operations of Rs. 382,167 lakhs, marking a steady performance for the fiscal year. The company’s consolidated profit for the year stood at Rs. 103,598 lakhs, compared to Rs. 92,758 lakhs in the previous year. For the final quarter (Q4) ending March 31, 2026, the company recorded a profit of Rs. 27,786 lakhs.
Dividend and Shareholder Information
The Board of Directors has recommended a final dividend of Rs. 57 per equity share (on a face value of Rs. 10 per share) for the financial year ended March 31, 2026. This recommendation is subject to the approval of shareholders at the 101st Annual General Meeting, which will be held via video conferencing on Tuesday, June 30, 2026. Shareholders must note the record date of Friday, May 29, 2026, to be eligible for the dividend payout, which is expected to be made on or after July 1, 2026.
Operational Highlights and Updates
The company confirmed that it is not classified as a Large Corporate entity as of March 31, 2026, as it does not have outstanding long-term borrowings exceeding Rs. 1,000 crores. Furthermore, the firm has clarified that it has only one reportable business segment, which is Pharmaceuticals. The annual results also reflect the incremental impact of recent labour code changes, which resulted in an increase of Rs. 1,182 lakhs in employee benefits expenses for the year.
Source: BSE
